Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Tagrisso Put on Priority Path in Japan for 1st-Line EGFR-Mutated NSCLC
AstraZeneca said on February 5 that the Japanese health ministry has granted priority review status to its EGFR tyrosine kinase inhibitor (TKI) Tagrisso (osimertinib) as a front-line treatment for inoperable or recurrent EGFR mutation-positive non-small cell lung cancer (NSCLC).In Japan,…
To read the full story
Related Article
- Tagrisso Filed for 1st-Line EGFR-Mutated NSCLC in Japan: AZ
November 28, 2017
BUSINESS
- MSD Debuts HIV Drug Idvynso in Japan in World-First Launch
April 16, 2026
- GSK’s Long-Acting Asthma Drug Exdensur Now Available in Japan
April 16, 2026
- Shionogi’s CVC Makes First Investment in Restore Vision
April 16, 2026
- Mochida Partners with Qilu on Gonal-f Biosimilar Development
April 16, 2026
- Astellas Kicks Off Global PIII of KRAS G12D Degrader Setidegrasib
April 16, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…